Theratechnologies ^Company

Theratechnologies Inc., a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that increases the target protein's resistance to enzymatic degradation. Its lead product is tesamorelin, whichcompleted its phase III clinical trial for the treatment of HIV-associated lipodystrophy and is in phase II clinical trials for the treatment of mild cognitive impairment and growth hormone deficient abdominal obesity.